Contact Us
Chengguan District, Lanzhou, Gansu, China
© 2025 Jeifer Pharmaceutical, All Right
Reserved.
The intermediate of Avibactam Sodium BP EP USP refers to a crucial raw material used during the commercial production of Avibactam, a beta-lactamase inhibitor widely valued in modern antibiotics. This material stands out as a foundational chemical building block. Its formation, purity, and handling set the tone for the safety, quality, and reliability of the final pharmaceutical product. In practice, this intermediate exhibits solid-state characteristics, often appearing as a crystalline powder or flakes. This structural consistency ties directly to strict regulatory standards tied to European Pharmacopoeia (EP), United States Pharmacopeia (USP), and British Pharmacopoeia (BP) specifications. Many labs prize the intermediate both for its stability and for its predictable transformation into the active ingredient.
On the lab bench, the intermediate of Avibactam Sodium stands out because of its clear white to off-white solid form. Chemists often observe the powder or crystalline appearance, with uniform grain sizes lending themselves to reproducible results during synthesis. It possesses a distinct molecular formula, typically noted as C8H10N3NaO6S (as dictated by specific product forms). This translates into a precise molecular weight, vital for dosage controls and yield predictions. Its density—measured in grams per cubic centimeter—plays a role in storage, shipping, and process batch calculations.
The intermediate falls under Harmonized System (HS) Code 29349990, which covers specialized organic compounds and intermediates for pharmaceutical use. This classification not only streamlines customs and export, but also highlights regulatory oversight regarding transport safety. From a molecular perspective, the compound displays notable chemical robustness under ambient conditions, an aspect pharmaceutical process engineers appreciate when scaling up batches. Its strong ionic bonds (courtesy of the sodium salt) and predictable crystal lattice shape help guard against unintentional degradation during routine handling. The formula also allows chemists to perform reliable stoichiometric calculations, critical for cost-effective manufacturing and environmental safety compliance.
Pharma-grade intermediates of Avibactam sodium most commonly present as free-flowing powders or aggregated flakes. On rare occasions, some manufacturers refine the product into pearl-like granules to improve handling in large reactors. Unlike many industrial chemicals, this intermediate rarely appears as a liquid or amorphous solid, thanks to the strength of its crystalline lattice and the need for moisture control. Chemists see dry powdered forms as an advantage—these forms store well, minimize the risk of decomposition, and allow precise dosing. Whether poured into a beaker or weighed on analytical balances, the physical profile reflects the hard-earned rigor of pharma manufacturing.
The density of the Avibactam sodium intermediate gives process engineers a solid starting point for bulk material storage and batch solution calculations. Reports often indicate values in the range of 1.3 to 1.6 g/cm³, though this can shift slightly based on hydration level and crystal form. Solubility in water remains moderate, providing the flexibility to process the molecule in aqueous environments common to bulk pharmaceutical manufacturing. That said, the intermediate shows sensitivity to excess humidity, with proper storage practices calling for tightly sealed containers, low moisture environments, and temperature control around 2–8ºC to guard against caking or clumping. Oversight in these areas not only keeps material integrity high but also staves off downstream issues in the manufacturing pipeline.
Anyone working hands-on with Avibactam sodium intermediates learns fast that, despite clear pharmaceutical value, every intermediate brings its own hazard profile. Labels read “harmful if swallowed”—emphasizing the gap between raw material and finished, approved antibiotics. Personal protective equipment (PPE), fume extraction, and careful waste disposal protocols make a difference, especially in labs where batches scale into the kilogram range. Contact with skin or eyes can trigger irritation. Even “pharma grade” does not eliminate the real risks that come with powerful chemical synthesis, meaning oversight and up-to-date safety data sheets stay at the center of every operation. I’ve seen colleagues take shortcuts, resulting in preventable near-misses—so discipline here becomes not just a box-ticking exercise but a culture of shared responsibility.
Pharmaceutical intermediates rarely come with “one-size-fits-all” chemical properties. With Avibactam sodium, it’s the stable balance between reactivity and inertness that stands out. The intermediate reacts cleanly under catalytic conditions to form critical Avibactam rings, but resists ambient oxidation or hydrolysis, key for shelf-life and inventory turnover. Every property—whether it be pH, melting point, or thermal stability—earns regular checks to keep production standards up. Should the chemical structure veer from specifications, the cascade of setbacks, both in terms of lost material and delayed production, often reaches well beyond any one batch or operator. This kind of risk turns quality assurance from a “nice to have” to the make-or-break factor in pharma supply chains.
I know from years in industry that regulatory authorities do not just look at the final pills or vials—they trace back every intermediate, check batch records, and demand documentation proving material identity and purity. One missed solvent residue, one out-of-spec crystal habit, and an entire lot sits on hold, investment frozen. The stringent nature of BP, EP, and USP protocols reflects not just the caution, but the learning from past industry failures. Every intermediate—especially such as this Avibactam sodium type—demands traceability, from raw materials through to final formulation. For companies, stringent record-keeping and reliable third-party certificates of analysis function as insurance both for patient safety and market access.
Efforts now focus on developing intermediates with fewer hazardous byproducts, scalable green chemistry routes, and packaging innovations that reduce contamination risk. Automated powder handling and robust online monitoring reduce errors and protect the health of workers and environments. Future regulatory trends will likely demand digital batch tracking, deeper impurity profiling, and more sustainable transport requirements. Small steps—better seals, smarter bulk drums, faster on-site purity checks—steadily close the gap between an intermediate’s safe journey in a lab and its final, lifesaving use in hospitals. As someone who has worked hands-on at every stage from procurement to scaling up batches, I can say that transparent communication across labs, suppliers, and regulators often does more to avert problems than the toughest policy. The value of a reliable intermediate like that of Avibactam sodium never stays on paper; it translates into safety at every patient’s bedside, every pharmacy, and every loading dock sending finished antibiotics into the world.
Chengguan District, Lanzhou, Gansu, China
